ScrutarSign up free

VEEVA SYSTEMS INC (VEEV)

SEC filings, insider trading & institutional ownership from EDGAR.

Veeva Systems is the leading provider of industry cloud solutions for the global life sciences industry, offering cloud software, data, and business consulting services designed for the strategic needs of pharmaceutical, biotechnology, and medical device and diagnostics companies across their research and development (R&D) and commercialization functions. Its offerings are organized into two major product families: Veeva Development Cloud, which includes application suites for clinical, regulatory, quality, and safety functions—such as Veeva Vault Clinical, Veeva Clinical Data Management Suite (CDMS), Veeva Clinical Operations Suite, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality—all built on its proprietary Veeva Vault platform to streamline end-to-end product development and regulatory compliance; and Veeva Commercial Cloud, which supports sales, medical affairs, and marketing functions through software like Veeva CRM, Veeva Vault PromoMats, Veeva Vault Medical, and Veeva Crossix, along with data offerings including Veeva OpenData, Veeva Link, and Veeva Compass that provide healthcare provider and patient data for customer engagement and analytics. The company also extends its content and data management capabilities to the consumer products and chemical (CP&C) industries through applications such as Veeva QualityOne, Veeva RegulatoryOne, and Veeva Claims.

Beyond software, Veeva provides strategic consulting through Veeva Consulting and professional services including implementation, systems integration, training, and managed services, often working alongside systems integrator partners like Accenture, Cognizant, and Tata Consultancy Services. As of January 31, 2023, Veeva served 1,388 customers, ranging from large global pharmaceutical and biotechnology companies such as Bayer, Boehringer Ingelheim, Eli Lilly, Gilead Sciences, Merck Sharp & Dohme, and Novartis, to emerging growth companies like Alkermes, Alnylam Pharmaceuticals, bluebird bio, Idorsia Pharmaceuticals, and Moderna, as well as contract sales and contract research organizations and companies in the CP&C industries. Veeva operates as a Delaware public benefit corporation, with a stated purpose of providing products and services that help make the industries it serves more productive while creating high-quality employment opportunities, and it competes in a global, rapidly evolving market against companies including IQVIA, Oracle, OpenText, Dassault Systèmes, Honeywell, Microsoft, Salesforce, and other specialized or legacy software providers.

AI-summarized from Item 1 (Business) of the company's most recent 10-K filing.

RevenueFY2026
$3.20B
▲ 16.3%YoY
Net incomeFY2026
$908.91M
▲ 27.3%YoY
Diluted EPSFY2026
$5.44
▲ 25.9%YoY
Gross margin
75.5%
▲ 100 bpsYoY
Insider net6 mo
−217.3K
shares6 sells0 buys
Institutions
47
$13.91B held

Financials

As reported to the SEC via XBRL, no adjustments

All financials →
Revenue & net income
$1B$2B$3B$4B
FY2023FY2024FY2025FY2026
RevenueNet income
FY2026 highlightsfrom 10-K
Gross profit$2.41B
Operating income$916.37M
Diluted EPS$5.44
Gross margin75.5%
Net margin28.4%

Latest filings

10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR

All filings →
FormFiledAccession
4Hung PriscillaSep 11, 2026EDGAR
4Wallach Matthew JSep 3, 2026EDGAR
4SEKHRI PAUL JSep 3, 2026EDGAR
4Ritter GordonSep 3, 2026EDGAR
4MOHR MARSHALLSep 3, 2026EDGAR
4Hung PriscillaSep 3, 2026EDGAR
4Hedley Mary LynneSep 3, 2026EDGAR
4Carges Mark TSep 3, 2026EDGAR

Insider trading

From Form 4 filings

All →
InsiderDateType
Hung PriscillaSep 9, 2026Sell
Cabral Timothy SSep 1, 2026Option exercise
Carges Mark TSep 1, 2026Option exercise
Hedley Mary LynneSep 1, 2026Option exercise
Hung PriscillaSep 1, 2026Option exercise

Top holders

13F & 13D/G · latest quarter

All →
HolderStakeFiledValue
BlackRock, Inc.7.9%Aug 7, 2026$2.28B
Vanguard Capital Management6.0%Aug 13, 2026$1.72B
Vanguard Portfolio Management4.6%Aug 13, 2026$1.32B
STATE STREET CORPORATION4.1%Aug 7, 2026$1.19B
AllianceBernstein L.P.3.0%Aug 14, 2026$863.07M

VEEV's filings are public. The insight is one click away.

Scrutar's AI reads every VEEV filing and surfaces what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.

Analyze VEEV filingsNo credit cardAI reports included on the free plan

Never miss a VEEV filing.

Get an email when VEEV files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Data as of Sep 15, 2026Source: SEC EDGAR.